Antimicrobial resistance (AMR) has been an ongoing threat to public health in South Africa as well as other countries in Africa. Disturbingly, the burden in the continent from infectious diseases has also been on the rise. Part of the reason is the persistence of infections associated with tropical regions as well as the higher rates of poverty and greater spread of drug resistance.
"Prof Kelly Chibale talks about the bonds he has formed through his illustrious career which began in an impoverished Zambian township."
Prof Chibale was featured in this weeks Noseweek Issue #241, 1st November 2019 By Sue Segar
Read the full story here
Africa accounts for 15% of the global population and 25% of the global disease burden, yet the discovery and development of medicines that end up in Africa has historically only happened in the global north. It is time for the situation to change, says Professor Kelly Chibale, director and founder of the University of Cape Town’s (UCT) Drug Discovery and Development Centre, H3D.
With African-led innovation in drug discovery lower than other continents, the government has a responsibility to address the barriers that stand in the way of creating an innovation-friendly environment.